Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2020; 26(3): 279-290
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.279
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.279
Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
Matthias Ocker, Department of Gastroenterology (CBF), Charité University Medicine Berlin, Berlin 10117, Germany
Author contributions: Ocker M is the sole author of this publication.
Conflict-of-interest statement: The author declares no conflict of interest related to this publication.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Matthias Ocker, MD, Professor, Department of Gastroenterology (CBF), Charité University Medicine Berlin, Berlin 10117, Germany. matthias.ocker@charite.de
Received: October 15, 2019
Peer-review started: October 15, 2019
First decision: December 4, 2019
Revised: December 17, 2019
Accepted: January 1, 2020
Article in press: January 1, 2020
Published online: January 21, 2020
Peer-review started: October 15, 2019
First decision: December 4, 2019
Revised: December 17, 2019
Accepted: January 1, 2020
Article in press: January 1, 2020
Published online: January 21, 2020
Core Tip
Core tip: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis show globally rising incidences and are expected to become the main reason for liver fibrosis, cirrhosis, liver cancer and end-stage liver disease with need for transplantation. Liver metabolism is, among other factors, regulated by fibroblast growth factors and their receptors. This review highlights the role of these signaling pathways in the context of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis and discusses novel treatment options for these otherwise difficult to treat diseases.